Ahmed F Soliman

Dr. Ahmed F Soliman


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2018 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
ASAhmed F Soliman
Ahmed F Soliman
LALobna M. Anees
Lobna M. Anees
DIDoaa M. Ibrahim
Doaa M. Ibrahim

1 August 2019 in Journal of Gastrointestinal Oncology
Verified
Journal Article
Closed access
PDF file
HHHala M. Hatab
Hala M. Hatab
FHFatma F. Abdel Hamid
Fatma F. Abdel Hamid
ASAhmed F Soliman
Ahmed F Soliman
TATamer A. Al-Shafie
Tamer A. Al-Shafie
YIYahia M. Ismail
Yahia M. Ismail
MEMotawa E. El-Houseini
Motawa E. El-Houseini
Background: Investigating and evaluating possible alternative therapeutic strategies to control hepatocellular carcinoma (HCC) is a critical need because of its high prevalence and being one of the most lethal cancers. Curcumin and taurine showed potent anti-tumor activities in pre-clinical and clinical studies by targeting multiple pathways. Thus, this study was designed to assess the effect of a combined treatment consisted of curcumin, piperine, and taurine on circulating levels of interleukin-10 (IL-10), and microRNAs miR-141 and miR-21. Methods: Twenty eligible HCC patients administrated an oral dose of 4 g curcumin, 40 mg piperine, and 500 mg taurine daily for three successive treatment cycles, each was a 30-day. The level of IL-10 along with the expression levels of miR-141, and miR-21 were monitored in serum before starting the treatment and after each cycle. Patients were followed-up for a period of 24 months. Results: The combined treatment was able to produce a significant decrease in the levels of serum IL-10, and miR-21 while it resulted in a non-significant up-regulation of serum miR-141 expression level. At the end of the follow-up period, the median overall survival (OS) rate was found to be 17.00 months with a worse OS in patients with high baseline levels of circulating IL-10 and miR-21 compared to those with low levels. In contrast, a low baseline level of circulating miR-141 was associated with poor prognosis. Conclusions: The combined treatment may be able to increase the OS rate by altering the circulating level of IL-10 and miR-21.

1 February 2019 in Life Sciences
Verified
Journal Article
Closed access
ASAhmed F Soliman
Ahmed F Soliman
MSMostafa Saif-Elnasr
Mostafa Saif-Elnasr
SFSalma M. Abdel Fattah
Salma M. Abdel Fattah

7 May 2021 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
YYYomna H. Youssef
Yomna H. Youssef
SMSara M. Makkeyah
Sara M. Makkeyah
ASAhmed F Soliman
Ahmed F Soliman
NMNefissa H. Meky
Nefissa H. Meky

23 July 2021 in Clinical and Experimental Medicine
Verified
Journal Article
Closed access
PDF file
HAHany M. M. Abdel Allah
Hany M. M. Abdel Allah
WZWalid E. Zahran
Walid E. Zahran
SESamir A. El-Masry
Samir A. El-Masry
MEMahmoud El-Bendary
Mahmoud El-Bendary
ASAhmed F Soliman
Ahmed F Soliman

11 October 2018 in Environmental Science and Pollution Research
Verified
Journal Article
Closed access
PDF file
SFSalma M. Abdel Fattah
Salma M. Abdel Fattah
MSMostafa Saif-Elnasr
Mostafa Saif-Elnasr
ASAhmed F Soliman
Ahmed F Soliman